June 29, 2017
Eli Lilly and Company completed a $90-million expansion of its Biotechnology Center in San Diego. Lilly’s new space helps foster and accelerate the discovery of medicines within the company’s core therapeutic areas of immunology, diabetes, oncology and neurodegeneration, as well as the emerging area of pain.
The new facility at 10290 Campus Point Dr. is part of the global healthcare company’s $850-million investment into expanding its U.S. operations. Lilly’s David A. Ricks said, “Today, as part of that commitment, we are pleased to say our research footprint in San Diego has been expanded.”
The center features a new technologically-advanced laboratory and an additional 180,000 square feet of working space, an increase of 145% over its former facility. In addition to the center’s established presence in preclinical and clinical immunology research, the new space allows for closer partnership between Lilly experts in biotechnology, discovery chemistry and research technologies.
For comments, questions or concerns, please contact Dennis Kaiser